Analyst consensus rating
United Therapeutics Analyst Rating: Buy
Direct answer
United Therapeutics's consensus rating is Buy.
13 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $651.15.
Forecast evidence checked October 15, 2026.
Get free United Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $540.03
- Average price target
- $651.15
- High price target
- $728.00
- Low price target
- $321.00
- Low target gap
- -40.6%
- Target upside
- +20.6%
- High target gap
- +34.8%
- Target range width
- 75.4%
- Consensus rating
- Buy
- Analysts
- 13
- Evidence date
- October 15, 2026
- Valid through
- October 22, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for United Therapeutics?
United Therapeutics has a verified Buy consensus. The same dataset has an average price target of $651.15.
How far are United Therapeutics's low and high targets from the recorded price?
The low target implies -40.6%, while the high target implies +34.8%.
How many analysts are included in United Therapeutics's consensus?
The verified consensus includes 13 analysts.
How is United Therapeutics's target upside or downside calculated?
The average target of $651.15 is divided by the recorded price of $540.03, then one is subtracted to produce +20.6%. This does not guarantee a future return.
When was United Therapeutics's analyst forecast verified?
The data was verified on 2026-10-15. The dataset is valid through 2026-10-22.